Agendia BV’s MammaPrint Gets FDA Approval

February 7, 2007 – A privately held Dutch biotech, Agendia BV, scored a big win today when it got approval from the FDA for its breast cancer recurrence test, MammaPrint®. MammaPrint® analyzes gene expression profiles of 70 known cancer genes in a cancer sample to predict whether a woman is at risk for recurrence from breast cancer. The company also has a test to determine the tissue type of a tumor of unknown origin, called CupPrint®. The approval puts pressure on Genomic Health, which markets a similar test. More details...

Back to news